Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) obtained approval for two new indications of its Hetrombopag Olamine Tablets from China's National Medical Products Administration.
The first indication is for the treatment of adult patients with thrombocytopenia caused by chemotherapy-based anti-tumor therapy for solid tumors, according to a Thursday bourse filing.
The other indication is for pediatric patients over six years of age with chronic primary immune thrombocytopenia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.